Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells

Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure

(2020) Jordan Gauthier et al.   BLOOD

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions

(2020) Uri Greenbaum et al.   Frontiers in Oncology

Antagonism of IAPs enhances CAR T cell efficacy

(2019) Jessica Michie et al.   Cancer Immunology Research

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

(2019) Dongrui Wang et al.   Jove-Journal of Visualized Experiments

Mechanisms of resistance to CAR T cell therapy

(2019) Nirali N. Shah et al.   Nature Reviews Clinical Oncology

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

(2019) Mohamed-Reda Benmebarek et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients

(2019) Sophia Stock et al.   INTERNATIONAL JOURNAL OF CANCER

Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells

(2019) LEI WANG et al.   CYTOTHERAPY

Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas

(2019) Xuan Zhang et al.   LEUKEMIA

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

(2019) Katrin Mestermann et al.   Science Translational Medicine

Clinical lessons learned from the first leg of the CAR T cell journey

(2019) Robbie G. Majzner et al.   NATURE MEDICINE

Eradication of Hepatocellular Carcinoma by NKG2D-Specific CAR-T Cells

(2019) Bin Sun et al.   Cancer Immunology Research

Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma

(2019) Victoria M. Smith et al.   HAEMATOLOGICA

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity

(2019) Wenyan Fu et al.   Nature Communications

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia

(2019) Katja Seipel et al.   Cancers

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

(2018) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells

(2018) Zhaodong Li et al.   LEUKEMIA

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

(2018) Jean-Marc Hoffmann et al.   Frontiers in Immunology

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines

(2018) Delphine Merino et al.   CANCER CELL

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

(2018) Daniel A. Pollyea et al.   NATURE MEDICINE

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

(2017) Cameron J. Turtle et al.   JOURNAL OF CLINICAL ONCOLOGY

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

(2017) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase

(2017) Alec J. Walker et al.   MOLECULAR THERAPY

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

(2017) Joel D. Leverson et al.   Cancer Discovery

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma

(2015) M. Klanova et al.   CLINICAL CANCER RESEARCH

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

(2015) A. N. Hata et al.   Cancer Discovery

CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells

(2015) Alexander J. Davenport et al.   Cancer Immunology Research

Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+T Cells

(2014) Keisuke Watanabe et al.   JOURNAL OF IMMUNOLOGY

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy

(2013) S C H Karlsson et al.   CANCER GENE THERAPY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function

(2010) David Warde-Farley et al.   NUCLEIC ACIDS RESEARCH